[Effects of Hodgkin cytotoxic serum on blast transformation of normal and Hodgkin human peripheral blood lymphocytes].
The PHA-resposiveness of normal and Hodgkin patient human peripheral blood lymphocytes has been studied before and after incubation with Hodgkin cytotoxic sera. The following conclusions have been reached: (a) Hodgkin cytotoxic serum is capable of decreasing the PHA-responsiveness of normal lymphocytes and of furtherly impairing the already defective PHA-responsiveness of Hodgkin lymphocytes. (b) The impaired PHA-responsiveness can be restored to the original levels by eluting the cytotoxic antibody. Control experiments in which normal and Hodgkin lymphocytes were put in contact with normal and Hodgkin non-cytotoxic serum showed no decrease of PHA-responsiveness. These data are in agreement with the hypothesis that the presence of serum cytotoxin is at least partly responsible for the immuno-incompetence of T-lymphocytes characteristic of Hodgkin's disease.
D000961:Antilymphocyte Serum; D003601:Cytotoxicity Tests, Immunologic; D006689:Hodgkin Disease / Q000276:immunology*; D006801:Humans; D037102:Lectins; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*
D000961:Antilymphocyte Serum; D037102:Lectins
Effetto del siero citotossico di pazienti con malattia di Hodgkin sulla PHA-responsività in vitro di linfociti periferici umani